Literature DB >> 16471319

Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells.

H Zhu1, X P Chen, S F Luo, J Guan, W G Zhang, B X Zhang.   

Abstract

Aim of the study was to explore the influence of hypoxia on multidrug resistance related genes and the potential role of hypoxia-inducible factor-1-alpha (HIF-1alpha) in formation of multidrug resistance in HepG2 human hepatocellular carcinoma cell line. HepG2 cells were subjected to hypoxia in a cohort of exposed time. A cell model stably expressing HIF-1alpha was established by liposome-mediated transfection of plasmid pcDNA3/HIF-1alpha into HepG2 cells. Apoptosis of HepG2 cells exposed to hypoxia or transfected by plasmid pcDNA3/HIF-1alpha was detected by Flow Cytometry after administration of chemotherapeutic drug (5-Fu). Real-time fluorescent quantitative PCR and Western-blot technique were used to analyze the expressions of multidrug resistance related genes mdr1, MRP1 and LRP at mRNA and protein level, respectively. Apoptosis Index of HepG2 cells exposed to hypoxia stepped down as exposed time extended after administration of 5-Fu. The expression of mdr1, MRP1 and LRP gene and protein revealed a hypoxic time-dependent induction and was synchronous with the alterations of HIF-1alpha in HepG2 cells exposed to hypoxia. The expressions of these multidrug resistance related genes were remarkably increased in HIF-1alpha transfected HepG2 cells as compared to empty vector transfected cells. Apoptosis index of HIF-1alpha transfected cells was obviously less than that of control cells when they were simultaneously exposed to 5-Fu for 24hrs. In conclusion, ambient hypoxia might be one of the causes for the formation of multidrug resistance in HepG2 human hepatocellular carcinoma cell line. Hypoxia-elicited multidrug resistance related protein expression might be a pathway for resistance of HepG2 cells to chemotherapeutics and HIF-1alpha might be involved in this process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16471319

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  30 in total

1.  Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model.

Authors:  Bing Yu; Mei-Hong Li; Wei Wang; Ying-Qing Wang; Yi Jiang; Sheng-Ping Yang; Jian-Min Yue; Jian Ding; Ze-Hong Miao
Journal:  J Mol Med (Berl)       Date:  2012-03-10       Impact factor: 4.599

2.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

3.  Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.

Authors:  Takashi Niizeki; Shuji Sumie; Takuji Torimura; Junichi Kurogi; Ryoko Kuromatsu; Hideki Iwamoto; Hajime Aino; Masahito Nakano; Atsushi Kawaguchi; Tatsuyuki Kakuma; Michio Sata
Journal:  J Gastroenterol       Date:  2012-03-01       Impact factor: 7.527

4.  A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics.

Authors:  Xian Xu; Chandran R Sabanayagam; Daniel A Harrington; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2014-01-18       Impact factor: 12.479

Review 5.  Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors:  Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 6.  Three-dimensional in vitro tumor models for cancer research and drug evaluation.

Authors:  Xian Xu; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biotechnol Adv       Date:  2014-08-10       Impact factor: 14.227

Review 7.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 8.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

Review 9.  Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.

Authors:  Daniel Lin; Jennifer Wu
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells.

Authors:  Dawei Li; Liang Zhou; Jiameng Huang; Xiyan Xiao
Journal:  Oncol Lett       Date:  2016-06-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.